Business Wire

Opengear Launches CM8100 Console Manager Enabling Simplified Device Management at Scale for Data Centers

7.6.2022 15:00:00 EEST | Business Wire | Press release

Share

Opengear, a Digi International company (NASDAQ, DGII, www.digi.com/) and leading network resilience solutions provider, announced today that it is launching its new family of console managers, the CM8100. As the latest addition to its award-winning Smart OOBTM Console Server family, the CM8100 delivers a comprehensive solution, adding NetOps capabilities to existing Smart OOB features that simplify connectivity to IT equipment. Moreover, it provides resilient and secure remote access to infrastructure devices while enhancing security and automation for better smart out-of-band management.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220607005005/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

As the latest addition to its award-winning Smart OOB Console Server family, Opengear's CM8100 delivers a comprehensive solution, adding NetOps capabilities to existing Smart OOB features that simplify connectivity to IT equipment. Moreover, it provides resilient and secure remote access to infrastructure devices while enhancing security and automation for better smart out-of-band management. (Photo: Business Wire)

“IT infrastructure needs to be resilient and easy to manage without relying on the network to manage the network,” says Gary Marks, President of Opengear. “Whether IT teams need to bring up new devices, manage existing ones or remediate outages, they must have resilient access to the network from anywhere. Regardless of the state of the production network, Opengear’s CM8100 provides engineers with the remote and reliable connectivity they need to be successful. It is yet another milestone in our long line of solutions designed to help engineers overcome today’s challenges such as travel requirements, security restrictions, and a lack of connectivity.”

CM8100 highlights:

  • Hosts up to 48 managed serial connected devices
  • Hardware-based TPM 2.0 security module providing data encryption and secure boot
  • Open architecture REST API based firmware supporting automation tools, Docker, and Python scripting
  • Four times faster than the previous generation while maintaining power-efficient and passively cooled operation up to 50C
  • Dual AC power supplies with independent monitoring and alerting

The Opengear platform and CM8100 enhance console access with modern automation capabilities. The CM8100 also helps IT personnel remotely provision, manage and remediate devices. Likewise, it enables remote access to even the most sprawling and complex infrastructure, such as switches, routers, PDUs, firewalls, and other critical data center equipment. Additionally, CM8100 appliances establish secure VPN tunnels which connect IT, staff, to remote devices. This provides local access to Ethernet and RS-232 console ports via standard UTP patch cables. The resilient connection of the CM8100 is available to either IT staff or applications to configure managed devices.

“Nearly every enterprise is familiar with the ‘3 a.m.’ call about a down server or a network device but driving or even flying to a data center or remote site can be time-consuming and expensive,” adds Marks. “More than half of IT outages cost over $100,000, so network issues must get fixed quickly. However, if engineers can’t access the network remotely and lack visibility, they will arrive at the site without the right tools or replacement devices to be successful in one trip. With the Opengear platform, IT personnel have the visibility to ascertain the problem from afar and also the access to remediate the outage remotely, saving considerable time and resources.”

For more information about the CM8100, visit https://opengear.com/products/cm8100-console-server/.

To learn more about Opengear, visit: www.opengear.com.

About Opengear

Opengear, a Digi International company, delivers secure, resilient access and automation to support critical IT infrastructure, even when the network is down. Provisioning, orchestration, and remote management of network devices through innovative software and appliances enable technical staff to reliably and efficiently manage data centers and remote network locations. Opengear solutions are trusted by global organizations across financial, digital communications, retail and manufacturing industries. The company is headquartered in New Jersey, with R&D centers in Silicon Valley and Brisbane, Australia. Opengear was acquired by Digi International in 2019, bringing together two organizations with a deep commitment to providing the best products, software and services that meet the demands of mission-critical networks. For more information, please visit www.opengear.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Opengear Contact
Peter Ramsay / Lora Metzner
Global Results Communications
open@globalresultspr.com
949.307.5908

UK/Ireland/Scotland: Opengear Media Relations Contact – Whiteoaks International
Kate Hellig
kateh@whiteoaks.co.uk
+44 (0) 1252 727313 (ext 124)

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye